Joshua Bauml, MD, an assistant professor at Perelman School of Medicine at the University of Pennsylvania, discusses the possibilities with using liquid biopsies in patients with lung cancer.
Joshua Bauml, MD, an assistant professor at Perelman School of Medicine at the University of Pennsylvania, discusses the possibilities with using liquid biopsies in patients with lung cancer.
By using liquid biopsies, it may be possible to assess tumor mutation burden, which is a major problem with immunotherapy in lung cancer, Bauml says. A study published inNaturealso looked at liquid biopsies in patients with lung cancer and discovered a potential approach to predicting relapse based on when circulating tumor DNA (ctDNA) appears.
Bauml suggests that liquid biopsies can also be used to monitor patients and would be more efficient than typical scans. The blood test results from a liquid biopsy can provide a visual image of the genetic landscape in each patient. This could ultimately help doctors see exactly how the patient is reacting to whichever therapy they are receiving.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More